These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24277175)

  • 21. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
    Gallien S; Delaugerre C; Charreau I; Braun J; Boulet T; Barrail-Tran A; de Castro N; Molina JM; Kuritzkes DR
    AIDS; 2011 Mar; 25(5):665-9. PubMed ID: 21326075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
    Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raltegravir.
    Croxtall JD; Lyseng-Williamson KA; Perry CM
    Drugs; 2008; 68(1):131-8. PubMed ID: 18081377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
    Raffi F; Wainberg MA
    Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
    Elbasha EE; Szucs T; Chaudhary MA; Kumar RN; Roediger A; Cook JR; Opravil M
    HIV Clin Trials; 2009; 10(4):233-53. PubMed ID: 19723611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
    Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV
    Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
    Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
    Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium.
    Patten G; Puthanakit T; McGowan CC; Wools-Kaloustian K; Hazra R; Pinto JA; Machado D; Succi R; Sohn AH; Rabie H; Musick B; Davies MA;
    J Int AIDS Soc; 2020 Jul; 23(7):e25580. PubMed ID: 32722897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance.
    Kuroishi N; Watananbe A; Sakuma R; Ruzicka DJ; Hara M
    PLoS One; 2019; 14(1):e0210384. PubMed ID: 30625208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.
    Hatano H; Scherzer R; Wu Y; Harvill K; Maka K; Hoh R; Sinclair E; Palmer S; Martin JN; Busch MP; Deeks SG; Hsue PY
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):317-25. PubMed ID: 22918156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.
    Pallikkuth S; Fischl MA; Pahwa S
    J Infect Dis; 2013 Nov; 208(10):1613-23. PubMed ID: 23922374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raltegravir with optimized background therapy for resistant HIV-1 infection.
    Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
    N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
    Gandhi RT; Zheng L; Bosch RJ; Chan ES; Margolis DM; Read S; Kallungal B; Palmer S; Medvik K; Lederman MM; Alatrakchi N; Jacobson JM; Wiegand A; Kearney M; Coffin JM; Mellors JW; Eron JJ;
    PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20711481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.